

Kathy Rouan



Kathy Rouan was appointed SVP and Head of Projects, Clinical Platforms and Sciences (PCPS) in May 2016, following a 27 year career in GSK in a range of discovery and development roles. She was recently appointed the leader of the Medicine Development Leaders.

She joined GSK in 1989, focusing on formulation development of protein pharmaceuticals. In 1993 Kathy moved into Project Leadership and Management becoming VP and Head of Metabolism and Pulmonary Project Management in 1999. She continued to lead Projects in a number of Therapeutic areas including Cardiovascular, Immunoinflammation and Gastroenterology Therapy areas. In 2007, Kathy led the development, submission and approval of Arzerra (ofatumumab) in refractory CLL. In 2012, she became Head of Biopharmaceutical Development responsible for delivery of GSK's portfolio of biopharmaceutical medicines. In December 2013, Kathy was appointed SVP and Head of R&D Stiefel, GSK's Dermatology therapy area unit.

Kathy holds a Ph.D. in Pharmaceutical Sciences from the University of Rhode Island, and a B.Pharm from the University of London. She resides in Pennsylvania and holds dual citizenship in US and UK.